cd4+ t cells

Melanoma

M.D. Anderson Cancer CenterCell therapyPhase 1Dormant

C

37/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 65/ 100

Competitive context

329 Active assets in the Melanoma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Primmune Therapeutics, Inc.	Phase 4	BB
DACARBAZINE Suzhou BlueHorse Therapeutics Co., Ltd.	Phase 3	BB
Ipilimumab M.D. Anderson Cancer Center	Phase 4	BB
Epirubicin Primmune Therapeutics, Inc.	Phase 4	BB
Nivolumab Bristol-Myers Squibb	Phase 4	BB

View all 50 →

Same molecule, other indications

cd4+ t cells is also rated in:

SarcomaDormant

C

Indicative ·

39 / 100

acute lymphoblastic leukemiaDormant

D

Indicative ·

30 / 100

acute myeloid leukemiaDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.